Comparative Pharmacology
Head-to-head clinical analysis: FAZACLO ODT versus SEROQUEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAZACLO ODT versus SEROQUEL.
FAZACLO ODT vs SEROQUEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clozapine is an atypical antipsychotic that antagonizes serotonin 5-HT2A and dopamine D2 receptors, with higher affinity for 5-HT2A. It also blocks muscarinic M1, histaminergic H1, and adrenergic α1 and α2 receptors.
Antagonist at dopamine D2 and serotonin 5-HT2A receptors; also blocks histamine H1 and adrenergic α1 receptors.
Clozapine (FAZACLO ODT) is an atypical antipsychotic. For schizophrenia, the typical starting dose is 12.5 mg orally once daily or twice daily, titrated by 25-50 mg/day to a target dose of 300-450 mg/day divided, up to a maximum of 900 mg/day. For treatment-resistant schizophrenia, the target dose is 300-450 mg/day, with doses above 500 mg/day requiring slower titration. The oral disintegrating tablet is taken sublingually or swallowed whole.
Initial: 25 mg twice daily; titrate by 25-50 mg twice daily on day 2 and 3 to target 300-400 mg daily in 2-3 divided doses. Maintenance: 400-800 mg daily. Maximum: 800 mg daily.
None Documented
None Documented
Terminal elimination half-life: 14 hours (range 6-26 hours) at steady state; increases with dose/duration. Context: Twice-daily dosing achieves steady state in 5-7 days.
Terminal elimination half-life approximately 7 hours for quetiapine; for metabolite N-desalkylquetiapine (norquetiapine), approximately 12 hours. Steady-state reached within 2 days.
Renal: 50% as metabolites (30% conjugated, 20% desmethylclozapine), 30% as unchanged; Fecal: 30% (biliary/fecal elimination of metabolites).
Primarily hepatic metabolism; <1% excreted unchanged renally. Metabolites excreted in urine (73%) and feces (20%).
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic